Impact of COVID-19 Pandemic on the Use of Antidepressant and Antianxiety Pharmaceuticals as Well as Sick Leave in Poland

Dominika Krupa, Marcin Czech, Jarosław Pinkas and Anna Mosiołek
Additional contact information
Dominika Krupa: Faculty of Management, University of Warsaw, 02-678 Warsaw, Poland
Marcin Czech: Department of Pharmacoeconomics, Institute of Mother and Child, 01-211 Warsaw, Poland
Jarosław Pinkas: School of Public Health, Centre of Postgraduate Medical Education, 01-826 Warsaw, Poland
Anna Mosiołek: Department of Psychiatry, Faculty of Health Sciences, Medical University of Warsaw, 05-802 Pruszków, Poland

IJERPH, 2022, vol. 19, issue 4, 1-11

Abstract: The COVID-19 pandemic caused a major upheaval to the lives of people and placed a strain on societal mental health. The aim of this research is to estimate the impact of the pandemic on the mental condition of the Polish population measured through the consumption of relevant medication and medical leave of absence from the workplace. Methods: We analyzed national-level data on the consumption of pharmaceuticals used in clinical practice in Poland in the treatment of depression and anxiety alongside medical absence in the workplace using the Interrupted Time Series model to estimate the significance of the pandemic. Results: We found no significant change regarding the consumption of pharmaceuticals with the development of the pandemic. Conversely, medical leaves of absence for psychiatric reasons increased significantly with the onset of COVID-19. The influence was strongest in the diagnosis of anxiety or reaction to severe stress and weakest in recurrent depression. Conclusion: The pandemic had a significant influence on the ability to work for psychiatric patients in Poland but did not change pharmaceutical use. Physicians should consider the mental health of patients impacted by the anti-epidemic measures. Further study is needed to fully understand the long-term impact of the pandemic on mental health in Poland.

Keywords: COVID-19; mental health; antidepressants; antianxiety; pharmaceuticals; sick leave; depression; anxiety; Poland (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/4/2135/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/4/2135/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:4:p:2135-:d:748910

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().